aid: angiex

name: Angiex

image: https://angiex.com/ASSETS/IMG/news/_1200x630_crop_center-center_none/news-default.png

description: 'Angiex is developing first‑in‑class Nuclear‑Delivered Antibody‑Drug Conjugates™ (ND‑ADCs) to address cancer lethality. The company aims to make cancer a non‑lethal disease, leveraging novel biology to deliver safe and effective therapies. Over one‑third of people in developed countries develop cancer, with 10 million deaths annually; Angiex’s vision is that no one should die of cancer.'

url: https://raw.githubusercontent.com/api-evangelist/angiex/refs/heads/main/apis.yml

x-type: company

x-source: harvest:secondary-market

x-tier: profiled
x-tier-reason: enrichment pass 2026-09-24 (modular-v1; was harvest)

specificationVersion: '0.20'

created: '2026-09-24'

modified: '2026-09-24'

tags:
- Biotechnology
- Oncology
- Drug Development
- Antibody-Drug Conjugates
- Cancer Therapy
- Company
tags_raw:
- Biotechnology
- Oncology
- Drug Development
- Antibody‑Drug Conjugates
- Cancer Therapy
- Company

maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io

common:
- type: Hosts
  url: hosts/angiex-hosts.yml
- type: PrivacyPolicy
  url: https://angiex.com/privacy-policy/
- type: Newsroom
  url: https://angiex.com/news
- type: Documentation
  url: https://angiex.com/ASSETS/DOCS/Angiex-World_ADC_POSTER_Final.pdf
- type: Blog
  url: https://angiex.com/blog
- type: DomainSecurity
  url: security/angiex-domain-security.yml
- type: Website
  url: https://angiex.com/

apis: []

x-coverage:
  state: none
  reason: no-developer-program
  detail: Angiex provides only corporate website and PDF poster with no developer program or API documentation.
  evidence:
    - url: https://angiex.com/ASSETS/DOCS/Angiex-World_ADC_POSTER_Final.pdf
      status: 200
  checked: 2026-09-24
x-enrichment:
  date: '2026-09-24'
  status: enriched
  artifacts_added: 5
  pass: modular-v1
  engine: identity=local,contract=local,surfaces=local,docs=local